Halozyme (HALO) Adds Illumina (ILMN) Exec to Board

March 28, 2013 4:22 PM EDT Send to a Friend
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the appointment of Matt Posard to its Board of Directors. Posard is currently Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc. (Nasdaq: ILMN).

Mr. Posard has over two decades of experience in strategic and product marketing. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina's successful commercial entry into the life science sequencing market where it now holds significant market share alongside the company's array business. Prior to joining Illumina, he held a variety of positions with the product marketing team at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. He also oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company's BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. Mr. Posard holds a Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Management Changes

Add Your Comment